FDA Brief

Warning letters Drugs

FDA warning letter to

Vedic Lifesciences Pvt. Ltd.

MediumIssued Mar 9Posted Mar 17Center for Drug Evaluation and Research (CDER)

FDA warns Vedic Lifesciences over false final reports for three nonclinical drug studies.

What happened

FDA inspected Vedic Lifesciences from January 13 to 15, 2025, under its Bioresearch Monitoring Program. FDA found that final reports for three nonclinical studies falsely named Vedic as the testing facility and storage location, named Vedic personnel as study director or quality assurance staff, and were signed by Vedic personnel instead of the study directors. Vedic acknowledged outsourcing the studies and said it had withheld partner testing facility and study director details from sponsors.

What FDA found

  1. Final reports falsely named Vedic as the testing facility instead of the facility that performed the studies.

    21 CFR 58.185(a)(1)
  2. Final reports falsely named Vedic personnel as study director and quality assurance personnel instead of the actual study staff.

    21 CFR 58.185(a)(10)
  3. Final reports falsely identified Vedic as the storage location for specimens, raw data, and final reports.

    21 CFR 58.185(a)(13)
  4. Study directors did not sign the final reports; Vedic personnel not responsible for the studies signed them.

    21 CFR 58.185(b); 21 CFR 58.33

What FDA wants

Within 15 business days, notify FDA in writing of actions taken to prevent similar violations and provide supporting information if Vedic believes it is compliant.

Who should pay attention

  • sponsors relying on Vedic for toxicology study liaison
  • testing labs preparing Good Laboratory Practice (GLP) final reports
  • drug developers submitting nonclinical study data to FDA

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk